Program
SLX-2101
A development code. Also written as “SLx-2101” and “RTN-001”.
Its studies are mostly in Hypertension · Raynaud Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Retension Pharmaceuticals. | 31 open or running | phase 2since Nov 20, 2007 | Nov 20, 2007 | Mar 2027phase 2 · NCT07142356 |
| Response Pharmaceuticals | 10 open or running | phase 2since Sep 11, 2007 | Sep 11, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2007First study: phase 2 study in Raynaud DiseaseNew to Response PharmaceuticalsResponse Pharmaceuticals · NCT00528242 · 17 enrolled · Germany
- Nov 20, 2007Retension Pharmaceuticals.'s first studies: 2 phase 2 studies in HypertensionNew to Retension Pharmaceuticals.Retension Pharmaceuticals. · NCT00562614, NCT00562549
- Aug 19, 2025Phase 2 study in HypertensionRetension Pharmaceuticals. · NCT07142356 · 280 planned · United States
Ahead
- Mar 2027Primary completion: phase 2 study in HypertensionRetension Pharmaceuticals. · NCT07142356
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07142356Hypertension · United States | 2 | Recruiting | Retension Pharmaceuticals. | Mar 2027 | 280 |
| NCT00562614Hypertension · Germany | 2 | Completed | Retension Pharmaceuticals. | Dec 2007 | 38 |
| NCT00562549Hypertension · United Kingdom | 2 | Completed | Retension Pharmaceuticals. | Dec 2007 | 26 |
| NCT00528242Raynaud Disease · Germany | 2 | Completed | Response Pharmaceuticals | Mar 2008 | 17 |
How it is read
Names in the registry
- “SLx-2101”, 3 entries
- “RTN-001”, 1 entry
Codes read as this program: RTN001, SLX2101.
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Raynaud Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.